Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lifeloc Reports Second Quarter 2023 Results By: ACCESSWIRE August 04, 2023 at 09:25 AM EDT WHEAT RIDGE, CO / ACCESSWIRE / August 4, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2023. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.280 million in the second quarter of 2023, resulting in a quarterly net profit of $55 thousand, or $0.02 per diluted share. These results compare to net revenue of $2.180 million and quarterly net loss of $(202) thousand, or $(0.08) per diluted share in the second quarter of 2022. Revenue for the quarter increased 5% versus the second quarter last year, as demand continued to recover from the impact of the COVID-19 global pandemic and the government ordered shutdowns. Six-month net revenues of $4.445 million and a net profit of $1 thousand, or $0.00 per diluted share, compared to net revenue of $4.341 million and a net loss of $(346) thousand, or $(0.14) per diluted share, for the same six months of 2022. Total gross margin in the second quarter improved to 45.7% versus 30.4% for the same quarter last year. For the first six months of 2023 gross margin was 44.5% versus 34.7% for the same period last year. Margin improvement was the biggest difference over last year, resulting from a combination of price increases, lower depreciation, and reduced inefficiencies because of fewer supply constraints this year. The margin improvement along with a small sales increase was sufficient to offset the rising research and development investment for SpinDx and still result in a profitable second quarter and a breakeven first half of the year 2023. We believe our product line-up is strong. The new platforms LX9 and LT7 have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain favored in many law enforcement and international organizations. The workplace Phoenix® 6.0 BT and EV30 models have been gaining market share. And our Easycal® automated calibration station builds important protection around our brand with the only automated calibration available for portable breath alcohol testers. We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace testing to get a rapid and quantitative measure for a panel of drugs of abuse, beginning with a device that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's saliva. Testing has commenced to validate the SpinDx technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The LCMS data are validating the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology's robustness and convenience of operation. The release of our SpinDx saliva testing system for beta testing is expected this year and is projected to result in commercialization in 2024. We expect to accelerate development on combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system. "In the second quarter we experienced a loosening of supply chain constraints as well as healthy demand. As a result, a portion of our production backlog was satisfied this quarter with some carryover into the third quarter. We are optimistic that supply will no longer be a significant constraint to our normal order flow," commented Dr. Wayne Willkomm, President and CEO. "Keeping product flowing is critical to funding our biggest opportunity, which is pushing the SpinDx product platform across the finish line to commercialization. We anticipate that our research and development expenses will continue to rise in this final push. Charles Gonzales, Research and Development Manager, added, "We have moved into the next critical phase of the SpinDx product development cycle, now developing our custom microfluidic disk with the first targeted drug being cannabis. We have also added tests for cocaine and amphetamines and have initiated work to detect fentanyl for our subsequent drug panel. The project is maintaining good momentum. We continue with validation testing utilizing actual human samples obtained through the Colorado School of Public Health at the University of Colorado Anschutz, with results to date confirming SpinDx performance." About Lifeloc Technologies Lifeloc Technologies, Inc. (OTC PINK:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor. Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings. Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc. SpinDx™ is a trademark of Sandia Corporation. Amy Evans Lifeloc Technologies, Inc. http://www.lifeloc.com (303) 431-9500 LIFELOC TECHNOLOGIES, INC.Condensed Balance Sheets ASSETS CURRENT ASSETS: June 30, 2023 (Unaudited) December 31, 2022 Cash $ 1,913,499 $ 2,352,754 Accounts receivable, net 762,670 627,919 Inventories, net 2,904,064 2,732,463 Employee retention credit receivable - 107,575 Prepaid expenses and other 207,778 58,203 Total current assets 5,788,011 5,878,914 PROPERTY AND EQUIPMENT, at cost: Land 317,932 317,932 Building 1,928,795 1,928,795 Real-time Alcohol Detection And Recognition equipment and software 569,448 569,448 Production equipment, software and space modifications 1,162,803 1,147,992 Training courses 432,375 432,375 Office equipment, software and space modifications 216,618 216,618 Sales and marketing equipment and space modifications 226,356 226,356 Research and development equipment, software and space modifications 480,684 480,684 Less accumulated depreciation (3,199,561) (3,072,961) Total property and equipment, net 2,135,450 2,247,239 OTHER ASSETS: Patents, net 67,747 69,679 Deposits and other 500 500 Deferred taxes 320,376 321,429 Total other assets 388,623 391,608 Total assets $ 8,312,084 $ 8,517,761 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 329,839 $ 413,957 Term loan payable, current portion 50,652 50,028 Customer deposits 174,967 201,031 Accrued expenses 290,942 344,944 Deferred revenue, current portion 63,676 80,222 Reserve for warranty expense 46,500 46,500 Total current liabilities 956,576 1,136,682 TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,195,158 1,219,677 DEFERRED REVENUE, net of current portion 3,782 6,191 Total liabilities 2,155,516 2,362,550 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY: Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares outstanding 4,668,014 4,668,014 Retained earnings 1,488,554 1,487,197 Total stockholders' equity 6,156,568 6,155,211 Total liabilities and stockholders' equity $ 8,312,084 $ 8,517,761 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Income (Unaudited) Three Months Ended June 30, REVENUES: 2023 2022 Product sales $ 2,246,407 $ 2,144,813 Royalties 10,150 12,572 Rental income 23,789 22,639 Total 2,280,346 2,180,024 COST OF SALES 1,237,902 1,516,389 GROSS PROFIT 1,042,444 663,635 OPERATING EXPENSES: Research and development 395,781 352,910 Sales and marketing 300,075 276,669 General and administrative 284,116 293,421 Total 979,972 923,000 OPERATING INCOME (LOSS) 62,472 (259,365) OTHER INCOME (EXPENSE): Interest income 19,200 1,190 Interest expense (10,290) (10,817) Total 8,910 (9,627) NET INCOME (LOSS) BEFORE PROVISION FOR TAXES 71,382 (268,992 BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES (16,237) 67,462 NET INCOME (LOSS) $ 55,145 $ (201,530) NET INCOME (LOSS) PER SHARE, BASIC $ 0.02 $ (0.08) NET INCOME (LOSS) PER SHARE, DILUTED $ 0.02 $ (0.08) WEIGHTED AVERAGE SHARES, BASIC 2,454,116 2,454,116 WEIGHTED AVERAGE SHARES, DILUTED 2,454,116 2,454,116 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Income (Unaudited) Six Months Ended June 30, REVENUES: 2023 2022 Product sales $ 4,379,766 $ 4,256,570 Royalties 18,356 39,212 Rental income 46,778 44,878 Total 4,444,900 4,340,660 COST OF SALES 2,467,029 2,835,136 GROSS PROFIT 1,977,871 1,505,524 OPERATING EXPENSES: Research and development 792,547 742,934 Sales and marketing 587,958 553,306 General and administrative 603,131 646,254 Total 1,983,636 1,942,494 OPERATING INCOME (LOSS) (5,765) (436,970) OTHER INCOME (EXPENSE): Interest income 29,000 1,622 Interest expense (20,825) (21,727) Total 8,175 (20,105) NET INCOME (LOSS) BEFORE PROVISION FOR TAXES 2,410 (457,075) BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES (1,053) 111,037 NET INCOME (LOSS) $ 1,357 $ (346,038) NET INCOME (LOSS) PER SHARE, BASIC $ - $ (0.14) NET INCOME (LOSS) PER SHARE, DILUTED $ - $ (0.14) WEIGHTED AVERAGE SHARES, BASIC 2,454,116 2,454,116 WEIGHTED AVERAGE SHARES, DILUTED 2,454,116 2,454,116 Lifeloc Technologies, Inc.Condensed Statements of Stockholders' Equity (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Total stockholders' equity, beginning balances $ 6,101,423 $ 6,466,460 $ 6,155,211 $ 6,593,766 Common stock (no shares issued during periods): Beginning balances 4,668,014 4,668,014 4,668,014 4,650,812 Stock based compensation expense related to stock options - - - 17,202 Ending balances 4,668,014 4,668,014 4,668,014 4,668,014 Retained earnings: Beginning balances 1,433,409 1,798,446 1,487,197 1,942,954 Net income (loss) 55,145 (201,530) 1,357 (346,038) Ending balances 1,488,554 1,596,916 1,488,554 1,596,916 Total stockholders' equity, ending balances $ 6,156,568 $ 6,264,930 $ 6,156,568 $ 6,264,930 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Cash Flows Six Months Ended June 30, CASH FLOWS FROM OPERATING ACTIVITIES: 2023 2022 Net income (loss) $ 1,357 $ (346,038) Adjustments to reconcile net income to net cash provided from (used in) operating activities- Depreciation and amortization 132,088 267,455 Provision for inventory obsolescence, net change - 94,578 Deferred taxes, net change 1,053 (111,037) Stock based compensation expense related to stock options - 17,202 Changes in operating assets and liabilities- Accounts receivable (134,751) (173,583) Inventories (171,601) 273,224 Employee retention credit and income taxes receivable 107,575 - Prepaid expenses and other (149,575) (67,884) Accounts payable (84,118) (146,322) Customer deposits (26,064) 276 Accrued expenses (54,002) (58,337) Deferred revenue (18,955) (3,990) Net cash (used in) operating activities (396,993) (254,456) CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES: Purchases of property and equipment (14,811) (40,753) Patent filing expense (1,404) - Net cash (used in) investing activities (16,215) (40,753) CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: Principal payments made on term loan (26,047) (25,144) Net cash (used in) financing activities (26,047) (25,144) NET INCREASE (DECREASE) IN CASH (439,255) (320,353) CASH, BEGINNING OF PERIOD 2,352,754 2,571,668 CASH, END OF PERIOD $ 1,913,499 $ 2,251,315 SUPPLEMENTAL INFORMATION: Cash paid for interest $ 18,673 $ 19,575 SOURCE: Lifeloc Technologies, Inc. View source version on accesswire.com: https://www.accesswire.com/772208/Lifeloc-Reports-Second-Quarter-2023-Results Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Lifeloc Reports Second Quarter 2023 Results By: ACCESSWIRE August 04, 2023 at 09:25 AM EDT WHEAT RIDGE, CO / ACCESSWIRE / August 4, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2023. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.280 million in the second quarter of 2023, resulting in a quarterly net profit of $55 thousand, or $0.02 per diluted share. These results compare to net revenue of $2.180 million and quarterly net loss of $(202) thousand, or $(0.08) per diluted share in the second quarter of 2022. Revenue for the quarter increased 5% versus the second quarter last year, as demand continued to recover from the impact of the COVID-19 global pandemic and the government ordered shutdowns. Six-month net revenues of $4.445 million and a net profit of $1 thousand, or $0.00 per diluted share, compared to net revenue of $4.341 million and a net loss of $(346) thousand, or $(0.14) per diluted share, for the same six months of 2022. Total gross margin in the second quarter improved to 45.7% versus 30.4% for the same quarter last year. For the first six months of 2023 gross margin was 44.5% versus 34.7% for the same period last year. Margin improvement was the biggest difference over last year, resulting from a combination of price increases, lower depreciation, and reduced inefficiencies because of fewer supply constraints this year. The margin improvement along with a small sales increase was sufficient to offset the rising research and development investment for SpinDx and still result in a profitable second quarter and a breakeven first half of the year 2023. We believe our product line-up is strong. The new platforms LX9 and LT7 have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain favored in many law enforcement and international organizations. The workplace Phoenix® 6.0 BT and EV30 models have been gaining market share. And our Easycal® automated calibration station builds important protection around our brand with the only automated calibration available for portable breath alcohol testers. We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace testing to get a rapid and quantitative measure for a panel of drugs of abuse, beginning with a device that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's saliva. Testing has commenced to validate the SpinDx technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The LCMS data are validating the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology's robustness and convenience of operation. The release of our SpinDx saliva testing system for beta testing is expected this year and is projected to result in commercialization in 2024. We expect to accelerate development on combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system. "In the second quarter we experienced a loosening of supply chain constraints as well as healthy demand. As a result, a portion of our production backlog was satisfied this quarter with some carryover into the third quarter. We are optimistic that supply will no longer be a significant constraint to our normal order flow," commented Dr. Wayne Willkomm, President and CEO. "Keeping product flowing is critical to funding our biggest opportunity, which is pushing the SpinDx product platform across the finish line to commercialization. We anticipate that our research and development expenses will continue to rise in this final push. Charles Gonzales, Research and Development Manager, added, "We have moved into the next critical phase of the SpinDx product development cycle, now developing our custom microfluidic disk with the first targeted drug being cannabis. We have also added tests for cocaine and amphetamines and have initiated work to detect fentanyl for our subsequent drug panel. The project is maintaining good momentum. We continue with validation testing utilizing actual human samples obtained through the Colorado School of Public Health at the University of Colorado Anschutz, with results to date confirming SpinDx performance." About Lifeloc Technologies Lifeloc Technologies, Inc. (OTC PINK:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor. Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings. Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc. SpinDx™ is a trademark of Sandia Corporation. Amy Evans Lifeloc Technologies, Inc. http://www.lifeloc.com (303) 431-9500 LIFELOC TECHNOLOGIES, INC.Condensed Balance Sheets ASSETS CURRENT ASSETS: June 30, 2023 (Unaudited) December 31, 2022 Cash $ 1,913,499 $ 2,352,754 Accounts receivable, net 762,670 627,919 Inventories, net 2,904,064 2,732,463 Employee retention credit receivable - 107,575 Prepaid expenses and other 207,778 58,203 Total current assets 5,788,011 5,878,914 PROPERTY AND EQUIPMENT, at cost: Land 317,932 317,932 Building 1,928,795 1,928,795 Real-time Alcohol Detection And Recognition equipment and software 569,448 569,448 Production equipment, software and space modifications 1,162,803 1,147,992 Training courses 432,375 432,375 Office equipment, software and space modifications 216,618 216,618 Sales and marketing equipment and space modifications 226,356 226,356 Research and development equipment, software and space modifications 480,684 480,684 Less accumulated depreciation (3,199,561) (3,072,961) Total property and equipment, net 2,135,450 2,247,239 OTHER ASSETS: Patents, net 67,747 69,679 Deposits and other 500 500 Deferred taxes 320,376 321,429 Total other assets 388,623 391,608 Total assets $ 8,312,084 $ 8,517,761 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 329,839 $ 413,957 Term loan payable, current portion 50,652 50,028 Customer deposits 174,967 201,031 Accrued expenses 290,942 344,944 Deferred revenue, current portion 63,676 80,222 Reserve for warranty expense 46,500 46,500 Total current liabilities 956,576 1,136,682 TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,195,158 1,219,677 DEFERRED REVENUE, net of current portion 3,782 6,191 Total liabilities 2,155,516 2,362,550 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY: Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares outstanding 4,668,014 4,668,014 Retained earnings 1,488,554 1,487,197 Total stockholders' equity 6,156,568 6,155,211 Total liabilities and stockholders' equity $ 8,312,084 $ 8,517,761 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Income (Unaudited) Three Months Ended June 30, REVENUES: 2023 2022 Product sales $ 2,246,407 $ 2,144,813 Royalties 10,150 12,572 Rental income 23,789 22,639 Total 2,280,346 2,180,024 COST OF SALES 1,237,902 1,516,389 GROSS PROFIT 1,042,444 663,635 OPERATING EXPENSES: Research and development 395,781 352,910 Sales and marketing 300,075 276,669 General and administrative 284,116 293,421 Total 979,972 923,000 OPERATING INCOME (LOSS) 62,472 (259,365) OTHER INCOME (EXPENSE): Interest income 19,200 1,190 Interest expense (10,290) (10,817) Total 8,910 (9,627) NET INCOME (LOSS) BEFORE PROVISION FOR TAXES 71,382 (268,992 BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES (16,237) 67,462 NET INCOME (LOSS) $ 55,145 $ (201,530) NET INCOME (LOSS) PER SHARE, BASIC $ 0.02 $ (0.08) NET INCOME (LOSS) PER SHARE, DILUTED $ 0.02 $ (0.08) WEIGHTED AVERAGE SHARES, BASIC 2,454,116 2,454,116 WEIGHTED AVERAGE SHARES, DILUTED 2,454,116 2,454,116 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Income (Unaudited) Six Months Ended June 30, REVENUES: 2023 2022 Product sales $ 4,379,766 $ 4,256,570 Royalties 18,356 39,212 Rental income 46,778 44,878 Total 4,444,900 4,340,660 COST OF SALES 2,467,029 2,835,136 GROSS PROFIT 1,977,871 1,505,524 OPERATING EXPENSES: Research and development 792,547 742,934 Sales and marketing 587,958 553,306 General and administrative 603,131 646,254 Total 1,983,636 1,942,494 OPERATING INCOME (LOSS) (5,765) (436,970) OTHER INCOME (EXPENSE): Interest income 29,000 1,622 Interest expense (20,825) (21,727) Total 8,175 (20,105) NET INCOME (LOSS) BEFORE PROVISION FOR TAXES 2,410 (457,075) BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES (1,053) 111,037 NET INCOME (LOSS) $ 1,357 $ (346,038) NET INCOME (LOSS) PER SHARE, BASIC $ - $ (0.14) NET INCOME (LOSS) PER SHARE, DILUTED $ - $ (0.14) WEIGHTED AVERAGE SHARES, BASIC 2,454,116 2,454,116 WEIGHTED AVERAGE SHARES, DILUTED 2,454,116 2,454,116 Lifeloc Technologies, Inc.Condensed Statements of Stockholders' Equity (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Total stockholders' equity, beginning balances $ 6,101,423 $ 6,466,460 $ 6,155,211 $ 6,593,766 Common stock (no shares issued during periods): Beginning balances 4,668,014 4,668,014 4,668,014 4,650,812 Stock based compensation expense related to stock options - - - 17,202 Ending balances 4,668,014 4,668,014 4,668,014 4,668,014 Retained earnings: Beginning balances 1,433,409 1,798,446 1,487,197 1,942,954 Net income (loss) 55,145 (201,530) 1,357 (346,038) Ending balances 1,488,554 1,596,916 1,488,554 1,596,916 Total stockholders' equity, ending balances $ 6,156,568 $ 6,264,930 $ 6,156,568 $ 6,264,930 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Cash Flows Six Months Ended June 30, CASH FLOWS FROM OPERATING ACTIVITIES: 2023 2022 Net income (loss) $ 1,357 $ (346,038) Adjustments to reconcile net income to net cash provided from (used in) operating activities- Depreciation and amortization 132,088 267,455 Provision for inventory obsolescence, net change - 94,578 Deferred taxes, net change 1,053 (111,037) Stock based compensation expense related to stock options - 17,202 Changes in operating assets and liabilities- Accounts receivable (134,751) (173,583) Inventories (171,601) 273,224 Employee retention credit and income taxes receivable 107,575 - Prepaid expenses and other (149,575) (67,884) Accounts payable (84,118) (146,322) Customer deposits (26,064) 276 Accrued expenses (54,002) (58,337) Deferred revenue (18,955) (3,990) Net cash (used in) operating activities (396,993) (254,456) CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES: Purchases of property and equipment (14,811) (40,753) Patent filing expense (1,404) - Net cash (used in) investing activities (16,215) (40,753) CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: Principal payments made on term loan (26,047) (25,144) Net cash (used in) financing activities (26,047) (25,144) NET INCREASE (DECREASE) IN CASH (439,255) (320,353) CASH, BEGINNING OF PERIOD 2,352,754 2,571,668 CASH, END OF PERIOD $ 1,913,499 $ 2,251,315 SUPPLEMENTAL INFORMATION: Cash paid for interest $ 18,673 $ 19,575 SOURCE: Lifeloc Technologies, Inc. View source version on accesswire.com: https://www.accesswire.com/772208/Lifeloc-Reports-Second-Quarter-2023-Results
WHEAT RIDGE, CO / ACCESSWIRE / August 4, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended June 30, 2023. Second Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.280 million in the second quarter of 2023, resulting in a quarterly net profit of $55 thousand, or $0.02 per diluted share. These results compare to net revenue of $2.180 million and quarterly net loss of $(202) thousand, or $(0.08) per diluted share in the second quarter of 2022. Revenue for the quarter increased 5% versus the second quarter last year, as demand continued to recover from the impact of the COVID-19 global pandemic and the government ordered shutdowns. Six-month net revenues of $4.445 million and a net profit of $1 thousand, or $0.00 per diluted share, compared to net revenue of $4.341 million and a net loss of $(346) thousand, or $(0.14) per diluted share, for the same six months of 2022. Total gross margin in the second quarter improved to 45.7% versus 30.4% for the same quarter last year. For the first six months of 2023 gross margin was 44.5% versus 34.7% for the same period last year. Margin improvement was the biggest difference over last year, resulting from a combination of price increases, lower depreciation, and reduced inefficiencies because of fewer supply constraints this year. The margin improvement along with a small sales increase was sufficient to offset the rising research and development investment for SpinDx and still result in a profitable second quarter and a breakeven first half of the year 2023. We believe our product line-up is strong. The new platforms LX9 and LT7 have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI's (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain favored in many law enforcement and international organizations. The workplace Phoenix® 6.0 BT and EV30 models have been gaining market share. And our Easycal® automated calibration station builds important protection around our brand with the only automated calibration available for portable breath alcohol testers. We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc's proven capability to build easy-to-use portable testing equipment. We are focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk," to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace testing to get a rapid and quantitative measure for a panel of drugs of abuse, beginning with a device that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject's saliva. Testing has commenced to validate the SpinDx technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples. The LCMS data are validating the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology's robustness and convenience of operation. The release of our SpinDx saliva testing system for beta testing is expected this year and is projected to result in commercialization in 2024. We expect to accelerate development on combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system. "In the second quarter we experienced a loosening of supply chain constraints as well as healthy demand. As a result, a portion of our production backlog was satisfied this quarter with some carryover into the third quarter. We are optimistic that supply will no longer be a significant constraint to our normal order flow," commented Dr. Wayne Willkomm, President and CEO. "Keeping product flowing is critical to funding our biggest opportunity, which is pushing the SpinDx product platform across the finish line to commercialization. We anticipate that our research and development expenses will continue to rise in this final push. Charles Gonzales, Research and Development Manager, added, "We have moved into the next critical phase of the SpinDx product development cycle, now developing our custom microfluidic disk with the first targeted drug being cannabis. We have also added tests for cocaine and amphetamines and have initiated work to detect fentanyl for our subsequent drug panel. The project is maintaining good momentum. We continue with validation testing utilizing actual human samples obtained through the Colorado School of Public Health at the University of Colorado Anschutz, with results to date confirming SpinDx performance." About Lifeloc Technologies Lifeloc Technologies, Inc. (OTC PINK:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor. Forward Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings. Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc. SpinDx™ is a trademark of Sandia Corporation. Amy Evans Lifeloc Technologies, Inc. http://www.lifeloc.com (303) 431-9500 LIFELOC TECHNOLOGIES, INC.Condensed Balance Sheets ASSETS CURRENT ASSETS: June 30, 2023 (Unaudited) December 31, 2022 Cash $ 1,913,499 $ 2,352,754 Accounts receivable, net 762,670 627,919 Inventories, net 2,904,064 2,732,463 Employee retention credit receivable - 107,575 Prepaid expenses and other 207,778 58,203 Total current assets 5,788,011 5,878,914 PROPERTY AND EQUIPMENT, at cost: Land 317,932 317,932 Building 1,928,795 1,928,795 Real-time Alcohol Detection And Recognition equipment and software 569,448 569,448 Production equipment, software and space modifications 1,162,803 1,147,992 Training courses 432,375 432,375 Office equipment, software and space modifications 216,618 216,618 Sales and marketing equipment and space modifications 226,356 226,356 Research and development equipment, software and space modifications 480,684 480,684 Less accumulated depreciation (3,199,561) (3,072,961) Total property and equipment, net 2,135,450 2,247,239 OTHER ASSETS: Patents, net 67,747 69,679 Deposits and other 500 500 Deferred taxes 320,376 321,429 Total other assets 388,623 391,608 Total assets $ 8,312,084 $ 8,517,761 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 329,839 $ 413,957 Term loan payable, current portion 50,652 50,028 Customer deposits 174,967 201,031 Accrued expenses 290,942 344,944 Deferred revenue, current portion 63,676 80,222 Reserve for warranty expense 46,500 46,500 Total current liabilities 956,576 1,136,682 TERM LOAN PAYABLE, net of current portion and debt issuance costs 1,195,158 1,219,677 DEFERRED REVENUE, net of current portion 3,782 6,191 Total liabilities 2,155,516 2,362,550 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY: Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares outstanding 4,668,014 4,668,014 Retained earnings 1,488,554 1,487,197 Total stockholders' equity 6,156,568 6,155,211 Total liabilities and stockholders' equity $ 8,312,084 $ 8,517,761 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Income (Unaudited) Three Months Ended June 30, REVENUES: 2023 2022 Product sales $ 2,246,407 $ 2,144,813 Royalties 10,150 12,572 Rental income 23,789 22,639 Total 2,280,346 2,180,024 COST OF SALES 1,237,902 1,516,389 GROSS PROFIT 1,042,444 663,635 OPERATING EXPENSES: Research and development 395,781 352,910 Sales and marketing 300,075 276,669 General and administrative 284,116 293,421 Total 979,972 923,000 OPERATING INCOME (LOSS) 62,472 (259,365) OTHER INCOME (EXPENSE): Interest income 19,200 1,190 Interest expense (10,290) (10,817) Total 8,910 (9,627) NET INCOME (LOSS) BEFORE PROVISION FOR TAXES 71,382 (268,992 BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES (16,237) 67,462 NET INCOME (LOSS) $ 55,145 $ (201,530) NET INCOME (LOSS) PER SHARE, BASIC $ 0.02 $ (0.08) NET INCOME (LOSS) PER SHARE, DILUTED $ 0.02 $ (0.08) WEIGHTED AVERAGE SHARES, BASIC 2,454,116 2,454,116 WEIGHTED AVERAGE SHARES, DILUTED 2,454,116 2,454,116 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Income (Unaudited) Six Months Ended June 30, REVENUES: 2023 2022 Product sales $ 4,379,766 $ 4,256,570 Royalties 18,356 39,212 Rental income 46,778 44,878 Total 4,444,900 4,340,660 COST OF SALES 2,467,029 2,835,136 GROSS PROFIT 1,977,871 1,505,524 OPERATING EXPENSES: Research and development 792,547 742,934 Sales and marketing 587,958 553,306 General and administrative 603,131 646,254 Total 1,983,636 1,942,494 OPERATING INCOME (LOSS) (5,765) (436,970) OTHER INCOME (EXPENSE): Interest income 29,000 1,622 Interest expense (20,825) (21,727) Total 8,175 (20,105) NET INCOME (LOSS) BEFORE PROVISION FOR TAXES 2,410 (457,075) BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES (1,053) 111,037 NET INCOME (LOSS) $ 1,357 $ (346,038) NET INCOME (LOSS) PER SHARE, BASIC $ - $ (0.14) NET INCOME (LOSS) PER SHARE, DILUTED $ - $ (0.14) WEIGHTED AVERAGE SHARES, BASIC 2,454,116 2,454,116 WEIGHTED AVERAGE SHARES, DILUTED 2,454,116 2,454,116 Lifeloc Technologies, Inc.Condensed Statements of Stockholders' Equity (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Total stockholders' equity, beginning balances $ 6,101,423 $ 6,466,460 $ 6,155,211 $ 6,593,766 Common stock (no shares issued during periods): Beginning balances 4,668,014 4,668,014 4,668,014 4,650,812 Stock based compensation expense related to stock options - - - 17,202 Ending balances 4,668,014 4,668,014 4,668,014 4,668,014 Retained earnings: Beginning balances 1,433,409 1,798,446 1,487,197 1,942,954 Net income (loss) 55,145 (201,530) 1,357 (346,038) Ending balances 1,488,554 1,596,916 1,488,554 1,596,916 Total stockholders' equity, ending balances $ 6,156,568 $ 6,264,930 $ 6,156,568 $ 6,264,930 LIFELOC TECHNOLOGIES, INC.Condensed Statements of Cash Flows Six Months Ended June 30, CASH FLOWS FROM OPERATING ACTIVITIES: 2023 2022 Net income (loss) $ 1,357 $ (346,038) Adjustments to reconcile net income to net cash provided from (used in) operating activities- Depreciation and amortization 132,088 267,455 Provision for inventory obsolescence, net change - 94,578 Deferred taxes, net change 1,053 (111,037) Stock based compensation expense related to stock options - 17,202 Changes in operating assets and liabilities- Accounts receivable (134,751) (173,583) Inventories (171,601) 273,224 Employee retention credit and income taxes receivable 107,575 - Prepaid expenses and other (149,575) (67,884) Accounts payable (84,118) (146,322) Customer deposits (26,064) 276 Accrued expenses (54,002) (58,337) Deferred revenue (18,955) (3,990) Net cash (used in) operating activities (396,993) (254,456) CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES: Purchases of property and equipment (14,811) (40,753) Patent filing expense (1,404) - Net cash (used in) investing activities (16,215) (40,753) CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES: Principal payments made on term loan (26,047) (25,144) Net cash (used in) financing activities (26,047) (25,144) NET INCREASE (DECREASE) IN CASH (439,255) (320,353) CASH, BEGINNING OF PERIOD 2,352,754 2,571,668 CASH, END OF PERIOD $ 1,913,499 $ 2,251,315 SUPPLEMENTAL INFORMATION: Cash paid for interest $ 18,673 $ 19,575 SOURCE: Lifeloc Technologies, Inc. View source version on accesswire.com: https://www.accesswire.com/772208/Lifeloc-Reports-Second-Quarter-2023-Results